RARA抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00666(RARA Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P00666(RARA Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The retinoic acid receptor alpha (RARA) is a nuclear hormone receptor that regulates gene expression by binding to retinoic acid, a derivative of vitamin A. As a transcription factor, RARA forms heterodimers with retinoid X receptors (RXRs) to modulate cellular processes like differentiation, proliferation, and apoptosis. Dysregulation of RARA is strongly associated with acute promyelocytic leukemia (APL), where a chromosomal translocation fuses RARA with other genes (e.g., PML-RARA), creating an oncoprotein that blocks myeloid cell differentiation.

RARA antibodies are critical tools in research and diagnostics. They enable detection of RARA expression or its fusion proteins in APL via techniques like immunohistochemistry (IHC), Western blot, or fluorescence in situ hybridization (FISH). These antibodies also aid in studying RARA’s role in normal physiology, such as embryonic development and tissue homeostasis, as well as in other cancers (e.g., breast, lung) where RARA signaling may be altered.

Therapeutically, anti-RARA strategies include all-trans retinoic acid (ATRA), which binds RARA to degrade the PML-RARA fusion protein in APL. RARA antibodies help monitor treatment efficacy and resistance mechanisms. However, challenges remain in ensuring antibody specificity due to structural similarities among nuclear receptors. Advances in monoclonal antibody development continue to refine their application in both basic research and clinical contexts.